Detail akcie CRISPR Therap N online

Business Summary: CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Crispr Therapeutics AG revenues increased 63% to $2.6M. Net loss increased 37% to $451M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Biotechnology segment loss increase of 27% to $509.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$3.92 to -$5.14.